



www.bioinformation.net
Volume 21(6)



Research Article

Received June 01, 2025; Revised June 30, 2025; Accepted June 30, 2025, Published June 30, 2025

DOI: 10.6026/973206300211602

SJIF 2025 (Scientific Journal Impact Factor for 2025) = 8.478

2022 Impact Factor (2023 Clarivate Inc. release) is 1.9

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain after adequate peer/editorial reviews and editing entertaining revisions where required. The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required.

Edited by A Prashanth

E-mail: phyjunc@gmail.com

Citation: Snigdha *et al.* Bioinformation 21(6): 1602-1605 (2025)

Clinical spectrum of tuberculosis among HIV infected patients in India: Correlation with immunological status using CD4 counts

M.K. Snigdha, Krishnavajhala Padma Theja, Kondeti Ganga Bhavani, Chennakesavulu Dara*,
Pranavi Paloju & Shiva Kumar Nimma

Department of General Medicine, ESIC Medical College, Sanathnagar, Hyderabad-500038, India; *Corresponding author

Affiliation URL:

<https://mchderabad.esic.gov.in/>

Author contacts:

M K Snigdha - E-mail: dr.snigdhmk21@gmail.com; Phone: +91 70953 83888

Krishnavajhala Padma Theja - E-mail: padmatheja.13@gmail.com; Phone: +91 94907 29531
Kondeti Ganga Bhavani - E-mail: gangabhavani7447.gb@gmail.com; Phone: +91 94937 91477
Chennakesavulu Dara - E-mail: augnus2k3@gmail.com; Phone: +91 9441107627
Pranavi Paloju - E-mail: palojupranavi1217@gmail.com; Phone: +91 94912 50724
Shiva Kumar Nimma - E-mail: shivakumarnimma7264@gmail.com; Phone: +91 93904 54123

Abstract:

Tuberculosis (TB) remains a common and serious opportunistic infection among HIV-infected individuals, with clinical presentation closely tied to immune status. In this prospective study of 100 HIV-positive patients with TB, pulmonary TB predominated in those with CD4 counts >200, while extra pulmonary and disseminated TB were strongly associated with CD4 counts <200. Symptoms such as cough and fever were prevalent and radiographic findings varied with immune suppression levels. CD4 counts served as a critical marker in determining the clinical spectrum and severity of TB. These findings underscore the importance of CD4-based assessment in guiding timely diagnosis and targeted management of TB in HIV patients.

Keywords: Tuberculosis, HIV, CD4 count, pulmonary TB, extra pulmonary TB, immunological status, opportunistic infections.

Background:

Tuberculosis (TB) continues to be an important public health issue in resource-poor nations such as India, where TB and HIV co-exist very frequently [1]. The most potent recognized risk factor for latent to active TB progression is HIV infection, increasing the lifetime risk from 10% among immunocompetent persons to more than 60% in those who are co-infected. India, where the global burden of TB lies close to a quarter, is confronted by an added burden caused by the growing tide of HIV infections [2]. TB is the single most frequent opportunistic infection in HIV-infected persons and is usually due to reactivation of latent infection, although primary infection risk is also greatly heightened [3]. Clinical manifestation of TB among HIV-infected individuals is immune status-dependent; those with a good CD4 count present with classical pulmonary TB, whereas in advanced immunosuppression, atypical or extrapulmonary disease is more common [4]. Depressed CD4 count is related to characteristics such as disseminated TB, lack of cavitations and diagnostic complexity. Due to the overlap in symptoms with other opportunistic infections, correct diagnosis is usually based on thorough clinical and laboratory assessment [5]. It is important to know these associations to ensure early diagnosis and treatment of TB among HIV-infected patients, especially in resource-poor settings.

Materials and Methods:

This potential observational investigation was undertaken in 18 months, November 2018-April 2020, in Osmania General Hospital under coordination with TB Chest Hospital and ART Clinic. Consecutive samples consisting of 100 HIV-positive individuals were sampled on convenience basis. The study patients included both sexes over 12 years old, with the diagnosis of HIV by Rapid Test or ELISA and having clinical and investigative features of either pulmonary or extrapulmonary tuberculosis. Irrespective of whether or not they received antiretroviral therapy, patients were recruited. Exclusion criteria were patients under 12 years of age, those with a history of treated or defaulter TB and patients with other established causes of immunosuppression like diabetes, malignancies, hematological disorders, malnutrition, or patients on

immunosuppressive therapy. Following informed consent, the study participants who met the inclusion criteria were enrolled in the outpatient department. Data was collected on pre-tested structured proforma through patient interview, complete history-taking and thorough physical examination. Baseline investigations done for all the patients were complete blood count, ESR, liver function test, renal function test, sputum smear for acid-fast bacilli (three samples), chest X-ray (posteroanterior view) and related biochemical and bacteriological investigations according to clinical presentation. Fine-needle aspiration cytology (FNAC) or biopsy of palpable peripheral lymph nodes was done and the tissue was then subjected to histopathological study and Ziehl-Neelsen staining. CD4 counts were measured using flow cytometry on the Becton Dickinson FAC Scan system. Statistical analysis was conducted with SPSS version 28. Data entry was done on Microsoft Excel and descriptive statistics were employed for summarizing the baseline characteristics. Continuous variables were represented as mean $\pm$ standard deviation or median with interquartile range depending on whether the Shapiro-Wilk normality test gave significant results. Categorical data were reported as frequencies and proportions. The chi-square test was employed to test associations of qualitative variables. Data were also graphically represented using bar charts and pie charts where necessary.

Results:

Table 1 interprets that the study population was predominantly male, with the highest number of cases (46%) in the 30–39 year age group and a mean age of 33.66 ± 8.46 years. **Table 2** interprets that fever (78%) and cough (75%) were the most frequent presenting symptoms, followed by breathlessness (62%), weight loss (56%) and diarrhoea (50%), suggesting systemic involvement in HIV-TB co-infection. **Table 3** interprets that pulmonary TB was the most common clinical form (51%), followed by extrapulmonary TB (43%) and disseminated TB (6%). **Table 4** interprets that extrapulmonary and disseminated TB were more frequent among patients with CD4 counts <200, while sputum-positive PTB was predominantly seen in those with CD4 >200, indicating a significant association between immune suppression and disease pattern. **Table 5** interprets that

upper zone lesions were exclusively seen in patients with CD4 >200, while mid/lower zone lesions were predominantly observed in those with CD4 <200, suggesting typical radiological patterns vary with immune status. The tables herein identify significant clinical and radiological correlations in patients with HIV-TB co-infection. The predominance in males (76%) and greatest number of cases (46%) in the 30–39 years age group is reflected in **Table 1**. **Table 2** outlines symptoms on presentation as fever (78%) and cough (75%) were most prominent, followed by breathlessness, weight loss and gastrointestinal disturbance. **Table 3** illustrates that the most common presentation was pulmonary TB (51%), followed by extrapulmonary TB (43%) and disseminated TB (6%). **Table 4** shows a high association between type of TB and immune status—sputum-positive pulmonary TB correlated with CD4 >200, whereas extrapulmonary and disseminated TB were more common in patients with CD4 <200. **Table 5** indicates that upper zone lesions occurred exclusively in CD4 >200 patients and were highly correlated with sputum positivity, whereas mid/lower zone lesions were characteristic of CD4 <200 patients, demonstrating that radiographic patterns are highly correlated with the extent of immunosuppression.

Table 1: Age and sex distribution of study participants

Age Group (years)	Male (n=76)	Female (n=24)	Total (n=100)
<21	2 (2.6%)	1 (4.2%)	3 (3.0%)
21-29	23 (30.3%)	10 (41.7%)	33 (33.0%)
30-39	34 (44.7%)	12 (50.0%)	46 (46.0%)
40-49	12 (15.8%)	1 (4.2%)	13 (13.0%)
50-59	4 (5.3%)	0 (0.0%)	4 (4.0%)
≥60	1 (1.3%)	0 (0.0%)	1 (1.0%)

Table 4: Association between TB Type and CD4 Count

CD4 Count (cells/μL)	-ve PTB (n=37)	+ve PTB (n=14)	Disseminated TB (n=6)	EPTB (n=43)	Total
<50	18 (48.6%)	0 (0.0%)	6 (100%)	5 (11.6%)	29
50-200	12 (32.4%)	2 (14.3%)	0 (0.0%)	34 (79.1%)	48
>200	7 (18.9%)	12 (85.7%)	0 (0.0%)	4 (9.3%)	23
Total	37 (100%)	14 (100%)	6 (100%)	43 (100%)	100

Discussion:

This research points to the clinical and radiological range of tuberculosis in HIV-infected patients, underlining the role of immune status [6]. Male predominance (76%) and clustering of cases among the 30–39 years age group are in accordance with national figures and other studies and reflect the disease burden in the sexually active age group. The symptomatology prevalent in fever, cough and diarrhoea concurs with previous reports, but diarrhoea was higher in this group, potentially secondary to lower mean CD4 levels and higher immunosuppression [7]. The majority of patients presented with pulmonary TB (51%), followed by extra pulmonary (43%) and disseminated TB (6%), with the latter two presentations correlating with CD4 levels <200, consistent with other Indian reports [8]. The comparatively low rate of sputum positivity may be due to the fact that no culture was tested and more patients had non-cavitatory or lower zone lesions [9]. On radiology, infiltrative rather than fibrocavitatory lesions were found, with upper zone lesions being mostly noted in CD4 >200 patients and mid/lower zone lesions in patients with lower CD4 levels results that were statistically significant and in accordance with existing literature

Table 2: Presenting symptoms among HIV-TB Co-infected Patients

Symptom	Number of Patients	Percentage (%)
Fever	78	78.0
Cough	75	75.0
Weight loss	56	56.0
Breathlessness	62	62.0
Fatigue/Lethargy	50	50.0
Diarrhoea	50	50.0
Chest Pain	20	20.0
Anorexia	32	32.0
Nausea/Vomiting	34	34.0
Abdominal Distension	10	10.0
Jaundice	6	6.0
Headache	6	6.0
Seizures	6	6.0
Focal Neurological Deficit	2	2.0
Altered Sensorium	4	4.0
Skin Lesions	12	12.0
Mucous Membrane Lesions	8	8.0

Table 3: Clinical types of tuberculosis in study participants

Type of TB	Number of Patients	Percentage (%)
Pulmonary TB	51	51.0
Extrapulmonary TB	43	43.0
Disseminated TB	6	6.0

Table 5: Chest X-ray Findings by CD4 Count

CD4 Count (cells/μL)	Upper Zone Lesions	Mid/Lower Zone Lesions
<50	0	18
50-200	0	14
>200	17	2
Total	17 (33.3%)	34 (66.7%)

[10]. The median CD4 count was 133.78 cells/μL and the counts were significantly lower in patients with disseminated TB and sputum-negative presentations, confirming the role of immune suppression in modifying TB presentation [11]. Tuberculosis is one of the commonest opportunistic infection and chances of developing tuberculosis increases with decrease CD4 cell count [12]. These results confirm the relevance of CD4-based stratification for early diagnosis and individualized management of TB in HIV-infected patients [13]. Yet, the single-centre design of the study and small sample size are significant drawbacks, calling for larger multicentric studies for wider generalizability.

Conclusion:

With a significant percentage of extra pulmonary and sputum-negative cases linked to CD4 counts < 200 cells/μL, pulmonary TB was shown to be the most prevalent type among HIV-infected individuals in this investigation. These results highlight the necessity of increased clinical suspicion and customised diagnostic strategies, especially in immunocompromised patients exhibiting abnormal radiographic patterns.

References:

- [1] Karo B *et al.* *BMC Infect Dis.* 2017 **17**:517. [PMID: 28743248]
 - [2] Martinson NA *et al.* *Proc Am Thorac Soc.* 2011 **8**:288. [PMID: 21653530]
 - [3] Olatunji AA *et al.* *Indian J Tuberc.* 2016 **63**:74. [PMID: 27451814]
 - [4] Bruyn ED *et al.* *Lancet Microbe.* 2021 **2**:e375. [PMID: 34386782]
 - [5] Jung AC *et al.* *J Gen Intern Med.* 1998 **13**:131. [PMID: 9502375]
 - [6] Matsegora N *et al.* *Int J Mycobacteriol.* 2021 **10**:122. [PMID: 34558462]
 - [7] Wondimeneh Y *et al.* *BMC Res Notes.* 2012 **5**:331. [PMID: 22738361]
 - [8] Rao JS *et al.* *Diagn Cytopathol.* 2015 **43**:16. [PMID: 24862646]
 - [9] Salazar RA *et al.* *AIDS Patient Care STDS.* 2000 **14**:79. [PMID: 10743519]
 - [10] Mukadi Y *et al.* *Lancet.* 1993 **342**:143. [PMID: 8101257]
 - [11] Karunaratne AH *et al.* *Ceylon Med J.* 2018 **63**:143. [PMID: 30415520]
 - [12] Kesari SP *et al.* *Indian J Otolaryngol Head Neck Surg.* 2019 **71**:167. [PMID: 31275824]
 - [13] Ligidi T *et al.* *Ethiop Med J.* 2011 **49**:75. [PMID: 21796907]
-

DRAFT